| Date | Time | Source | Announcement |
|---|---|---|---|
| 28 Feb 2011 | 10:36 AM | Total voting rights | |
| 21 Feb 2011 | 07:00 AM | Half-yearly report | |
| 10 Feb 2011 | 07:00 AM | Issue of Equity | |
| 09 Feb 2011 | 10:22 AM | Statement re Share Price Movement | |
| 07 Feb 2011 | 06:00 AM | Research Update: Positive Leukaemia Model Study | |
| 31 Dec 2010 | 06:00 AM | Total voting rights | |
| 22 Dec 2010 | 07:00 AM | Issue of Options | |
| 15 Dec 2010 | 11:44 AM | Result of AGM | |
| 13 Dec 2010 | 07:00 AM | SAR Placing | |
| 02 Dec 2010 | 04:02 PM | Holding(s) in Company | |
| 25 Oct 2010 | 07:00 AM | Sareum to present at major research congress in... | |
| 22 Oct 2010 | 07:00 AM | Final Results | |
| 09 Sep 2010 | 02:44 PM | Holding(s) in Company | |
| 02 Sep 2010 | 11:41 AM | Holding(s) in Company | |
| 31 Aug 2010 | 12:06 PM | Total voting rights | |
| 03 Aug 2010 | 07:00 AM | Issue of Equity | |
| 12 Jul 2010 | 07:00 AM | Adviser - change of name | |
| 05 May 2010 | 07:00 AM | Sareum to Present at BIO 2010 | |
| 26 Apr 2010 | 07:00 AM | Scientific Advisory Board App | |
| 16 Mar 2010 | 07:00 AM | Collaboration Agreement | |
| 16 Feb 2010 | 07:00 AM | Half Yearly Report | |
| 20 Jan 2010 | 07:00 AM | The ICR, Sareum and CRT Limit | |
| 16 Dec 2009 | 11:01 AM | Result of AGM | |
| 04 Dec 2009 | 03:18 PM | Issue of options | |
| 24 Nov 2009 | 05:05 PM | Holding(s) in Company | |
| 20 Nov 2009 | 07:00 AM | Availability of Report & Acco | |
| 02 Nov 2009 | 07:00 AM | Sareum to Present at BIO-Euro | |
| 30 Oct 2009 | 07:00 AM | Total Voting Rights | |
| 27 Oct 2009 | 07:00 AM | Final Results | |
| 19 Oct 2009 | 02:49 PM | Holding(s) in Company | |
| 19 Oct 2009 | 07:00 AM | NOMAD - change of name | |
| 15 Oct 2009 | 09:52 AM | Holding(s) in Company | |
| 12 Oct 2009 | 05:02 PM | Issue of Equity | |
| 12 Oct 2009 | 07:00 AM | Issue of Equity | |
| 09 Oct 2009 | 04:11 PM | Holding(s) in Company | |
| 08 Oct 2009 | 07:00 AM | Holding(s) in Company | |
| 06 Oct 2009 | 07:00 AM | Cancer Research Programme to | |
| 30 Sep 2009 | 07:00 AM | Total Voting Rights | |
| 21 Sep 2009 | 07:00 AM | Holding(s) in Company | |
| 16 Sep 2009 | 04:15 PM | Holding(s) in Company | |
| 10 Sep 2009 | 07:00 AM | Holding(s) in Company | |
| 08 Sep 2009 | 07:00 AM | Issue of Equity | |
| 03 Sep 2009 | 10:57 AM | Holding(s) in Company | |
| 28 Aug 2009 | 12:57 PM | Statement re Share Price Move | |
| 05 Jun 2009 | 10:53 AM | Statement re. Bulletin Board | |
| 24 Apr 2009 | 11:03 AM | Holding(s) in Company | |
| 20 Apr 2009 | 01:22 PM | Holding(s) in Company | |
| 23 Mar 2009 | 03:08 PM | Holding(s) in Company | |
| 23 Mar 2009 | 12:56 PM | Statement re share price move | |
| 23 Feb 2009 | 07:00 AM | Half Yearly Report |
Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.
The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.
SAR share price listed on AIM in 2004 under the ticker SAR.